 |
|
Isoflavones and Postmenopausal Women—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: We appreciate the responses of Drs Alekel, Sirtori, and Muanza and colleagues to our study. Regarding Alekel’s methodological concerns, although the general assumption was that isoflavones are as effective as hormone therapy, for BMD power calculations we used data previously reported from an intervention that was quite similar to ours for an even shorter duration that included smaller groups of women.1 When we calculated that 200 participants were needed for this study, this calculation took into account a dropout rate of 25% for all women, for an eventual number of 75 participants in each intervention group, which is the number needed for the secondary per protocol analysis. The sample-size calculations were 2-sided and in agreement with the above assumptions. Our statistical adjustment for smoking history included current smoking and did not change the results. Additional adjustment for the use of antihypertensive medication also did not change our findings. . . . [Full Text of this Article]
Yvonne T. van der Schouw, PhD
y.t.vanderschouw@umcutrecht.nl
Diederick E. Grobbee, MD, PhD;
Linda Kok;
Sanne Kreijkamp-Kaspers
University Medical Center Utrecht
Utrecht, the Netherlands
RELATED ARTICLES
Isoflavones and Postmenopausal Women
D. Lee Alekel
JAMA. 2004;292(19):2336.
EXTRACT
| FULL TEXT
Isoflavones and Postmenopausal Women
Cesare R. Sirtori
JAMA. 2004;292(19):2336-2337.
EXTRACT
| FULL TEXT
Isoflavones and Postmenopausal Women
Dave N. Muanza, Alex Vasquez, John Cannell, and William P. Grant
JAMA. 2004;292(19):2337.
EXTRACT
| FULL TEXT
|
